Evommune (EVMN) Change in Accured Expenses (2024 - 2026)

Evommune (EVMN) has reported Change in Accured Expenses for 3 consecutive years, with -$4.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 128.97% year-over-year to -$4.8 million; the TTM figure through Mar 2026 stood at -$2.8 million (changed N/A YoY), while the FY2025 annual figure was $2.8 million, up 4.22% from the prior year.
• Change in Accured Expenses fell to -$4.8 million in Q1 2026 per EVMN's latest filing, from $4.3 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $4.3 million in Q4 2025 and bottomed at -$4.8 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged -$689500.0 across 3 years, with a median of -$1.1 million in 2024.
• Annual changes were most pronounced in 2025 — Change in Accured Expenses jumped 3169.29% — and 2026, when it tumbled 128.97%.
• Evommune's Change in Accured Expenses stood at -$140000.0 in 2024, then surged by 3169.29% to $4.3 million in 2025, then slumped by 212.01% to -$4.8 million in 2026.
• Business Quant data shows EVMN's Change in Accured Expenses at -$4.8 million in Q1 2026, $4.3 million in Q4 2025, and -$2.1 million in Q1 2025.